Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib long-term extension in rheumatoid arthritis
2016-003630-25Phase 3Completed
- Sponsor
- Galapagos NV
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of filgotinib in rheumatoid arthritis (RA), sponsored by Galapagos NV. Primary endpoint: Safety. Started Apr 2017; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-003630-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003630-25.